Frank words about breast screening by Baines, Cornelia J
Analysis and Comment                                                                                                                          Baines
Open Medicine 2011;5(3):e134
Frank words about breast 
screening 
Cornelia J. Baines
Cornelia J. Baines, MD, MSc, Fellow of the American College of Epi-
demiology, is Professor Emerita at the Dalla Lana School of Public 
Health, University of Toronto, Toronto, ON Canada.
Competing interests: None declared. 
Funding: None.
Correspondence: cornelia.baines@utoronto.ca
A 
growing body of evidence suggests that the 
benefits achieved by screening for breast cancer       
are small, that the harm from the over-diagnosis 
of breast cancer arising from screening is substantial, 
and that, where screening is available, the observed re-
ductions in breast cancer mortality arise largely from in-
creased awareness and improved chemo- and hormone 
therapy.1 In spite of these new insights, screening advo-
cacy continues in full crescendo. For example, in 2010 
the Canadian Breast Cancer Foundation Ontario (CB-
CFO) released a report on its recent consensus confer-
ence, “It’s About Time,” focusing on the earlier detection 
and diagnosis of breast cancer. The CBCFO is a not-for-
profit  organization;  its  conference  scientific  advisory 
committee consisted of five members, of whom three are 
active in breast imaging and a fourth is the director of 
cancer screening at the American Cancer Society. The 
breast cancer screening recommendations for women at 
average risk that emerged from the conference are that 
screening should be done within an organized program 
and should begin at “approximately” age 40. (“Approxi-
mately” may leave wiggle room for women in their 30s to 
participate.) The “preferred” modality described is an-
nual digital mammography, and if it is not available, film 
mammography is the alternative. 
The CBCFO’s campaign for women in their 40s to be 
included in the Ontario Breast Screening Program is less 
than  convincing  given  the  current  evidence.  Further-
more, vested interests from the imaging industry are a 
major factor associated with screening advocacy.2 De-
spite the lack of compelling evidence, the recently re-
leased 2011 budget for the Government of Ontario has 
earmarked $10 million to screen high-risk women aged 
30–49 for breast cancer. Such an initiative is compatible 
with the generally held belief that the earlier detection 
achieved by screening makes cure more likely. It is not 
compatible with current evidence. 
Commitment  and  funding  for  breast  screening  for 
women  aged  40–49  without  compelling  evidence  of 
benefit is not unique to Canada. An uproar among screen-
ing advocates was unleashed in November 2009 with 
the publication of the United States Preventive Services 
Task Force (USPSTF) Guidelines for Breast Screening.3 
The task force concluded that 1904 women aged 39 to 
49 needed to be invited for annual screening for 10 years 
to prevent one breast cancer death (leaving 1903 women 
at substantial risk of over-diagnosis). Corresponding fig-
ures for women aged 50–59 and 60–69 were 1339 and 
377 respectively. The guidelines are outlined in Textbox 
1. The USPSTF also recognized over-diagnosis as one of 
the harms of screening.4 
The  recommendations  “were  widely  and  loudly  de-
nounced by radiologists, breast cancer survivors, media 
doctors, gynecologists and politicians. Medical experts 
called the task force ‘idiots’ and conservatives lined up to 
denounce the report as an Obama administration plot.”5 
The  American  College  of  Radiology  (ACR)  declared 
that “two decades of decline in breast cancer mortality 
could be reversed and countless American women may 
die needlessly from breast cancer each year” and that 
the  recommendations  were  “flawed,”  “shocking”  and 
“unconscionable.”6 These protestations conveniently ig-
nored evidence from Italy, Denmark, Norway and the 
World Health Organization that,  primarily as a result of 
Textbox 1: Summary of United States Preventive Services 
Task Force (USPSTF) recommendations on screening for 
breast cancer3 
The USPSTF:
•  “recommends against routine screening mammography in women 
aged 40 to 49 years. The decision to start regular, biennial screening 
mammography before the age of 50 years should be an individual 
one and take into account patient context, including the patient’s 
values regarding speci￿  c bene￿  ts and harms.”
•  “recommends biennial screening mammography for women between 
the ages of 50 and 74 years.” 
•  “concludes that the current evidence is insu￿   cient to assess the 
additional bene￿  ts and harms of screening mammography in women 
75 years or older.”
•  “concludes that the current evidence is insu￿   cient to assess the 
additional bene￿  ts and harms of clinical breast examination beyond 
screening mammography in women 40 years or older.”
•  “recommends against clinicians teaching women how to perform 
breast self-examination.”
•  “concludes that the current evidence is insu￿   cient to assess 
additional bene￿  ts and harms of either digital mammography or 
magnetic resonance imaging instead of ￿  lm mammography as 
screening modalities for breast cancer.”Open Medicine 2011;5(3):e135
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increased breast cancer awareness and improved ther-
apy, breast cancer mortality has in fact declined in the 
absence of screening in screening-eligible women and 
also in women too young to be screened.7–10 
It is of interest that the ACR received donations of at 
least $1 million each from GE Healthcare and Siemens 
AG, both companies that make mammography equip-
ment and MRI scanners. The lobbyists leading the charge 
against the USPSTF 2009 guidelines in Washington in-
cluded GE, Siemens and the ACR.6 A US radiologist and 
screening advocate not only assailed the 2009 USPSTF 
Guidelines but also wrote that those disagreeing with 
him were wrong: “They distort data, rely on weak sci-
ence, but refuse to defend when challenged.”11 The claim 
was also made that “Many European countries as well 
as Canada do not support, or at any rate do not encour-
age, screening before the age of 50 and have lied to their 
populations.”11 
Over-diagnosis is now recognized as a major harm 
of screening.4,12–14 Over-diagnosis, according to the US 
National Cancer Institute website, is the diagnosis of “a 
neoplasm that would never become clinically apparent 
prior to a patient’s death without screening. An example 
is a tumor that is found by mammographic screening 
that  would  never  be  evident  otherwise.”15  It  has  been 
estimated that 25% or more of screen-detected breast 
cancers are over-diagnosed.4,12–14 How is this puzzling 
conclusion reached? When screening trials were being 
planned, it was predicted that screening would initially 
result in an increased incidence of early cancer. With 
screening bringing forward the date of diagnosis com-
pared to later clinical detection (lead time), the numbers 
of early breast cancers diagnosed were increased. This 
led to the assumption that later there would be a corres-
ponding decline in the incidence of invasive cancer in the 
screened population. In fact, US SEER data reveal that 
the expected correlation between an initial increase in 
early cancers and a later decline in invasive cancers did 
not occur in the period 1983–2005. The early increase 
occurred, but there was no subsequent decline in ad-
vanced cancers.13 Similar observations have been made 
in Europe,14 leading to the conclusion that there is a sub-
stantial  risk  of  over-diagnosis  arising  from  screening 
programs.  In  contrast  to  the  transitory  disadvantages 
of false-positive screens, the downside of over-diagnosis 
is that its consequences are life-long.12 Not only is treat-
ment unpleasant, but its long-term consequences (pain, 
deformity, and increased risk of cardiac complications) 
are significant. 
After many years of follow-up, combining data from 
screening  trials  demonstrates  a  significant  15%–16% 
reduction in overall breast cancer mortality.16,17 However, 
looking specifically at screening benefit for women aged 
40–49, the Swedish Overview revealed a 9%,18 the UK 
Age trial a 17%19 and the USPSTF a 15% reduction,16 none 
of which were statistically significant. When that “bene-
fit” is balanced against the 25% or more increased risk 
of screen-detected cancers that are over-diagnosed,12–14 
in addition to the recognized efficacy of current therapy,1 
mammography screening benefits are diminished. 
Perhaps  even  more  compelling  are  the  data  relat-
ing breast cancer mortality to the presence or absence 
of screening programs. A 2010 Danish study compared 
breast cancer death rates over the period 1971 to 2005 in 
20% of the Danish population living in counties where 
breast screening was offered for about 17 years, to death 
rates in the 80% of the population in counties where no 
screening occurred. Surprisingly, breast cancer deaths 
decreased as much in screened as unscreened popula-
tions  up  to  the  age  of  74.  Even  more  surprising  was 
the finding that breast cancer deaths declined even in 
younger women who were ineligible for screening and 
thus did not undergo routine screening to detect their 
cancers. No decline was observed in women over age 74, 
another group ineligible for screening in Denmark.7 
In addition, a recent overview of 30 European coun-
tries  using  WHO  data  has  shown  that  breast  cancer 
mortality dropped 37% in women under 50 years, who 
are generally ineligible for screening, while the drop was 
only 21% in women aged 50–69 years, who were most 
commonly screened.9 Improvement in therapy (such as 
chemo-  and  hormone  therapy)  since  the  1980s,  when 
many screening trials were conducted, have undoubted-
ly contributed to the breast cancer mortality reduction 
observed in both screened and unscreened women.
It’s  time  to  recognize  that  screening  benefits  in 
younger women are small in relation to the risks of over- 
diagnosis.  Screening advocates have used ad hominem 
attacks that, although inappropriate, have been very suc-
cessful  in  dominating  the  screening  controversy.5,6,11,20 
Survivors’  testimony  in  support  of  mammography 
screening  has  been  powerful,  even  though  it  is  in-
compatible with the reality that most women with breast 
cancer do not die of breast cancer. Their testimony is 
also incompatible with the reality that women who have 
been over-diagnosed never will die of their “cancer.” In 
addition, what the early breast cancer survivors may not 
be aware of is the sad fact that breast cancer can kill 20 
years after diagnosis.21 
As recently observed in the New England Journal of 
Medicine, we should “work to prevent vested interests 
from being granted the loudest voices in health care.”2 The vested interests in what has been termed “the mam-
mography wars”2 are clearly those in the imaging indus-
try, those involved directly in screening programs, and 
even those in the not-for-profit sector, whose fundraising 
capacity is enhanced by a public committed to fighting 
breast cancer. 
It is reasonable for women to choose to be screened, 
but only if they are completely informed about the prob-
ability  of  benefit  versus  the  probability  of  harm.  For 
2000 women aged 40–49 who undergo screening for 10 
years, the benefit is much smaller in terms of avoiding 
death from breast cancer than is the harm arising from 
over-diagnosis  and  unnecessary  treatment  for  breast 
cancer, to say nothing of the increased rates of mastec-
tomy associated with screening.22,23 These issues are not 
widely known to the general public. After over 20 years 
of involvement in the screening controversy, I can only 
conclude that this is information few want to hear and 
many want to suppress.
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